25^th World Congress on Neurology and Neurodisorders July 16-17, 2018 Melbourne, Australia

Dr. Brian Tran has completed his MD degree from St. George Medical School. He is board certified\r\nand serves at the Medical Director of NeuroActiva, Inc. Lloyd Tran is the CEO of NeuroActiva, a\r\nclinical-stage biopharmaceutical company dedicated to the discovery, development, and\r\ncommercialization of new drugs to treat Alzheimer’s disease.

Mild cognitive impairment (“MCI”) is defined as the “symptomatic pre-dementia stage” on the\r\ncontinuum of cognitive decline. Currently, no medications have proven effective for MCI.\r\nPreclinical experiments indicate that NA-831 is an endogenous small molecule that exhibits\r\nneuroprotection, neurogenesis, and cognitive protective properties across a range of disease models.\r\nNA-831 has been shown to be safe and well tolerated in healthy volunteers.